{
  "BRCA1": [
    {
      "name": "Olaparib (Lynparza)",
      "ic50": "0.22 nM",
      "confidence": 85,
      "description": "PARP inhibitor particularly effective in BRCA-mutated cancers. Prevents DNA repair in cancer cells.",
      "mechanism": "PARP enzyme inhibitor",
      "sideEffects": "Nausea, fatigue, anemia",
      "clinicalTrial": "Phase III OlympiAD"
    }
  ],
  "EGFR": [
    {
      "name": "Osimertinib (Tagrisso)",
      "ic50": "0.15 nM",
      "confidence": 88,
      "description": "EGFR tyrosine kinase inhibitor effective against T790M resistance mutations in NSCLC.",
      "mechanism": "EGFR tyrosine kinase inhibitor",
      "sideEffects": "Diarrhea, rash, nail toxicity",
      "clinicalTrial": "Phase III FLAURA study"
    }
  ],
  "HER2": [
    {
      "name": "Trastuzumab (Herceptin)",
      "ic50": "0.08 nM",
      "confidence": 91,
      "description": "Monoclonal antibody targeting HER2 protein overexpressed in breast cancers.",
      "mechanism": "HER2 receptor antagonist",
      "sideEffects": "Cardiotoxicity, infusion reactions",
      "clinicalTrial": "Phase III HERA study"
    }
  ],
  "PD-L1": [
    {
      "name": "Atezolizumab (Tecentriq)",
      "ic50": "0.20 nM",
      "confidence": 87,
      "description": "PD-L1 inhibitor enhancing immune system response in NSCLC and triple-negative breast cancer.",
      "mechanism": "Immune checkpoint inhibitor",
      "sideEffects": "Immune-related adverse events",
      "clinicalTrial": "IMpower110 trial"
    }
  ],
  "KRAS": [
    {
      "name": "Sotorasib (Lumakras)",
      "ic50": "0.17 nM",
      "confidence": 83,
      "description": "KRAS G12C inhibitor used in NSCLC patients with specific KRAS mutation.",
      "mechanism": "KRAS G12C covalent inhibitor",
      "sideEffects": "Diarrhea, nausea, fatigue",
      "clinicalTrial": "CodeBreaK 100 trial"
    }
  ],
  "ALK": [
    {
      "name": "Alectinib (Alecensa)",
      "ic50": "0.13 nM",
      "confidence": 90,
      "description": "Targeted therapy for ALK-positive NSCLC, crosses blood-brain barrier effectively.",
      "mechanism": "ALK tyrosine kinase inhibitor",
      "sideEffects": "Constipation, fatigue, edema",
      "clinicalTrial": "ALEX trial"
    }
  ],
  "PIK3CA": [
    {
      "name": "Alpelisib (Piqray)",
      "ic50": "0.25 nM",
      "confidence": 84,
      "description": "PI3K inhibitor used for advanced breast cancer with PIK3CA mutation.",
      "mechanism": "PI3K-alpha selective inhibitor",
      "sideEffects": "Hyperglycemia, rash, diarrhea",
      "clinicalTrial": "SOLAR-1 trial"
    }
  ]
}
